Yahoo Web Search

Search results

  1. People also ask

  2. Feb 14, 2023 · The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal ...

  3. Testing has been completed to support a shelf-life (expiration date) of up to 22 months. The BinaxNOW™ COVID-19 Antigen Self Test, part number 195-160 or 195- 180, may now have a longer than labeled product expiry date. All BinaxNOW COVID-19 Antigen Self Test kits currently have a twenty-two-month expiry date.

  4. Apr 29, 2022 · Abbott Diagnostics Scarborough, Inc.: BinaxNOWTM COVID-19 Ag Self Test 15-month to 22-month shelf-life extension granted by the FDA December 21, 2022. Lot Number.

  5. Abbott has designed the BinaxNOW™ COVID-19 Ag Card for decentralized testing, so you can test right at the point of care and get results for your patients quickly and easily. The BinaxNOW COVID-19 Ag Card test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).*. Check your lot expiration date extension.

  6. Mar 24, 2023 · The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal ...

  7. Nov 1, 2023 · Alternate brand name: GoodToKnow COVID-19 Antigen Rapid Test; Alternate brand name: GoToKnow COVID-19 Antigen Rapid Test; Shelf Life: 15 months; InBios International Inc: SCoV-2 Ag Detect Rapid ...

  8. Mar 22, 2023 · These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564 (b) (1) of the Act, 21 U.S.C. § 360bbb-3 (b) (1), unless the authorization is terminated or revoked sooner.

  1. People also search for